Search Results - "Drouyer, Matthieu"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    LRRK2 Phosphorylation, More Than an Epiphenomenon by Marchand, Antoine, Drouyer, Matthieu, Sarchione, Alessia, Chartier-Harlin, Marie-Christine, Taymans, Jean-Marc

    Published in Frontiers in neuroscience (16-06-2020)
    “…Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene are linked to autosomal dominant Parkinson's disease (PD), and genetic variations at the LRRK2 locus…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice by Drouyer, Matthieu, Merjane, Jessica, Nazareth, Deborah, Knight, Maddison, Scott, Suzanne, Liao, Sophia H Y, Ginn, Samantha L, Zhu, Erhua, Alexander, Ian E, Lisowski, Leszek

    Published in Molecular therapy (06-03-2024)
    “…Directed evolution of natural AAV9 using peptide display libraries have been widely used in the search for an optimal recombinant AAV (rAAV) for transgene…”
    Get more information
    Journal Article
  10. 10

    GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2 by Blanca Ramírez, Marian, Lara Ordóñez, Antonio Jesús, Fdez, Elena, Madero-Pérez, Jesús, Gonnelli, Adriano, Drouyer, Matthieu, Chartier-Harlin, Marie-Christine, Taymans, Jean-Marc, Bubacco, Luigi, Greggio, Elisa, Hilfiker, Sabine

    Published in Human molecular genetics (15-07-2017)
    “…Mutations in leucine-rich repeat kinase 2 (LRRK2) comprise the most common cause of familial Parkinson's disease (PD), and sequence variants modify risk for…”
    Get full text
    Journal Article
  11. 11

    LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker? by Taymans, Jean-Marc, Mutez, Eugénie, Drouyer, Matthieu, Sibran, William, Chartier-Harlin, Marie-Christine

    Published in Biochemical Society transactions (08-02-2017)
    “…Leucine-rich repeat kinase 2 (LRRK2) is a complex signalling protein that is a key therapeutic target, particularly in Parkinson's disease (PD). In addition,…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Investigating the neuroprotective effect of AAV-mediated β-synuclein overexpression in a transgenic model of synucleinopathy by Sargent, Dorian, Bétemps, Dominique, Drouyer, Matthieu, Verchere, Jérémy, Gaillard, Damien, Arsac, Jean-Noël, Lakhdar, Latifa, Salvetti, Anna, Baron, Thierry

    Published in Scientific reports (03-12-2018)
    “…Parkinson’s disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases characterized by inclusions mainly composed of α-synuclein (α-syn)…”
    Get full text
    Journal Article
  14. 14